Compare RUSHB & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUSHB | TGTX |
|---|---|---|
| Founded | 1965 | 1993 |
| Country | United States | United States |
| Employees | 7388 | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.9B |
| IPO Year | N/A | 2008 |
| Metric | RUSHB | TGTX |
|---|---|---|
| Price | $64.12 | $28.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $50.67 |
| AVG Volume (30 Days) | 41.0K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | N/A | $90.97 |
| Revenue Next Year | $1.77 | $45.74 |
| P/E Ratio | $16.53 | ★ $10.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $47.71 | $25.37 |
| 52 Week High | $67.27 | $46.48 |
| Indicator | RUSHB | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 44.72 |
| Support Level | $62.82 | $27.25 |
| Resistance Level | $67.19 | $33.05 |
| Average True Range (ATR) | 2.07 | 1.13 |
| MACD | -0.32 | 0.04 |
| Stochastic Oscillator | 30.37 | 27.69 |
Rush Enterprises Inc is a full-service, integrated retailer of commercial vehicles and related services. The company operates in a single segment; Truck Segment includes the operation of a network of commercial vehicle dealerships under the name Rush Truck Centers. It sells commercial vehicles manufactured by Peterbilt, International, Hino, Ford, Isuzu, IC Bus, and Blue Bird and also provides one-stop service for the needs of commercial vehicle customers, including retail sales of new and used commercial vehicles, aftermarket parts sales, service and repair facilities, financing, leasing and rental, and insurance products. The company's business is concentrated in the United States and Ontario, Canada commercial vehicle markets and related aftermarkets.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.